Vilon: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •5 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (4 countries listed)
Risk Assessment
Vilon has never been administered to humans in controlled clinical trials meeting Western regulatory standards (ICH-GCP). The complete absence of human safety data means the risk profile is entirely unknown. All safety inferences are theoretical or based on limited preclinical mouse studies from a single research group.
Nearly all vilon research originates from the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. The absence of independent replication is a significant scientific risk factor, as findings from single laboratories have historically shown lower reproducibility rates.
No pharmacokinetic studies have been published for vilon in any species. Absorption, distribution, metabolism, excretion, and bioavailability are completely unknown. Whether intact vilon reaches target tissues after any route of administration has not been demonstrated.
Vilon obtained from research peptide suppliers is not manufactured under GMP conditions. Research-grade products may contain impurities, endotoxins, or degradation products. Russian bioregulator capsule products may not meet Western pharmaceutical manufacturing standards.
No specific molecular target, receptor, or validated signaling pathway has been identified for vilon. Without understanding the mechanism, it is impossible to predict off-target effects, drug interactions, or contraindications.
⚠️Important Warnings
- •FOR RESEARCH USE ONLY: Vilon has not been tested in humans through Western regulatory clinical trials and is not approved for any clinical use by the FDA, EMA, or other Western regulatory authorities.
- •All published vilon research comes primarily from a single research group (Khavinson, St. Petersburg). Independent replication of efficacy claims is essentially absent. This represents a significant scientific limitation.
- •No pharmacokinetic data exists for vilon in any species. Whether intact vilon dipeptide is absorbed orally, survives serum degradation, or reaches target tissues is entirely unknown.
- •Russian bioregulator capsule products containing vilon have not been evaluated for quality, purity, potency, or efficacy by Western regulatory standards. Product authenticity cannot be independently verified.
- •The proposed epigenetic effects (chromatin remodeling, gene reactivation) have not been validated by modern methods (ChIP-seq, ATAC-seq) or by independent research groups.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Research | Not FDA-approved for any indication. Not scheduled as a controlled substance. Available as a research peptide from specialty suppliers. Not recognized as a dietary supplement ingredient under DSHEA. |
| European Union | Research | Not EMA-approved. Available for research purposes only. No clinical development programs registered with EudraCT. |
| Russia | Research | Vilon has been marketed as a dietary bioregulator supplement in capsule form. Russian regulatory standards differ from FDA and EMA requirements. Marketed under the Khavinson peptide bioregulator product line. |
| International | Research | Not approved for clinical use in any Western jurisdiction. Available as a research reagent from specialty peptide suppliers. No clinical trial registrations on ClinicalTrials.gov or other Western registries. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 15+ community reports
View community protocolsCritical Safety Information#
Vilon (L-Lys-L-Glu) is a preclinical research compound that has not been evaluated in clinical trials meeting Western regulatory standards. No human safety data exists from controlled studies. The following risk assessment is based on theoretical pharmacological considerations and limited preclinical observations from a single research group.
Risk Assessment#
No Human Safety Data#
The most significant risk factor for vilon is the complete absence of human safety data from controlled clinical trials:
- No phase 1 safety or tolerability studies have been conducted
- No human pharmacokinetic data exists
- No therapeutic index or dose-limiting toxicity has been established
- No adverse event monitoring has been conducted in humans
- No dose-response relationship has been characterized
Single Research Group Limitation#
Nearly all vilon research originates from the Khavinson group. This creates several risks:
| Concern | Implication |
|---|---|
| Publication bias | Negative results may not be published |
| Methodological consistency | Same methods and potential biases across all studies |
| Reproducibility | No independent confirmation of findings |
| Objectivity | Researchers have commercial interest in bioregulator products |
| Peer review depth | Many publications in low-impact or Russian-language journals |
Historical analysis of biomedical research has shown that findings from single laboratories replicate at substantially lower rates than those confirmed by multiple independent groups.
Pharmacokinetic Unknowns#
The absence of any pharmacokinetic data represents a fundamental gap:
- Oral bioavailability: Whether intact vilon survives GI digestion is unknown. As a dipeptide, it would be susceptible to rapid hydrolysis by gastric acid, pancreatic proteases, and brush border peptidases
- Serum stability: Dipeptidases are ubiquitous in blood plasma and would be expected to rapidly cleave vilon
- Tissue distribution: Whether intact vilon reaches proposed target tissues (thymus, lymphoid organs) has not been demonstrated
- Half-life: Expected to be very short (minutes) based on general dipeptide pharmacokinetics, but not formally measured
Unknown Mechanism#
Without an identified molecular target, receptor, or signaling pathway:
- Off-target effects cannot be predicted
- Drug interactions cannot be assessed
- Contraindications cannot be defined
- Dose-response relationship cannot be modeled
- Biomarkers for efficacy monitoring cannot be identified
Product Quality Risks#
Research-Grade Peptides#
Vilon obtained as a research peptide:
- Is not manufactured under GMP conditions
- May contain synthesis impurities, residual solvents, or endotoxins
- Certificate of analysis quality varies by supplier
- Not intended for human administration
Russian Bioregulator Products#
Vilon capsules marketed in Russia:
- Are not manufactured to FDA or EMA pharmaceutical standards
- Have not been independently tested for content verification
- May not contain validated quantities of intact vilon dipeptide
- Product authenticity and supply chain integrity cannot be verified from outside Russia
- Labels and documentation may not be available in English
Regulatory Status#
| Jurisdiction | Status | Details |
|---|---|---|
| United States | Research compound | Not FDA-approved; not a recognized dietary supplement ingredient |
| European Union | Research compound | Not EMA-approved; no EudraCT registrations |
| Russia | Bioregulator supplement | Marketed as dietary bioregulator; different regulatory framework |
| International | Research compound | No Western clinical development programs |
Risk Summary#
| Risk Category | Severity | Basis |
|---|---|---|
| Unknown human safety | High | No human clinical trial data |
| Single-group evidence | High | No independent replication |
| Pharmacokinetic unknowns | High | No ADME data in any species |
| Unknown mechanism | Moderate-High | No identified target or pathway |
| Product quality | Moderate | Non-GMP manufacturing |
| Epigenetic risks | Unknown | Chromatin remodeling claims not validated |
Recommendations#
Vilon should be used only for in vitro and in vivo research purposes under appropriate institutional protocols. Human administration outside of properly approved clinical trials (none of which currently exist) cannot be recommended based on the available evidence. The combination of single-group evidence, absent pharmacokinetic data, and unknown mechanism of action represents a level of scientific uncertainty that precludes informed risk assessment.
Related Reading#
Frequently Asked Questions About Vilon
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.